Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALCHEMIST Chemo-IO (ACCIO) in Resected NSCLC
NCT04267848Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2020
- Primary completion
- Jan 2030
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Disease Free Survival at 5 years. Started Jun 2020; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04267848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267848.